Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Vyriad

- PMLiVE

NICE recommends ALK’s immunotherapy to target underlying cause of hay fever

An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

- PMLiVE

BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

- PMLiVE

AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn

The companies will aim to develop tumour-activated immunotherapies, including masked T-cell engagers

- PMLiVE

Researchers develop immunotherapy to prevent prostate cancer treatment resistance

The second-most common cancer in the UK affects more than 52,000 men every year

- PMLiVE

Roche’s subcutaneous Tecentriq granted EC approval for multiple cancer types

The formulation reduces treatment time by around 80% compared to intravenous infusion

- PMLiVE

Gilead gains rights to Compugen’s immunotherapy programme in deal worth $848m

The high affinity antibody blocks the interaction between IL-18 binding protein and IL-18

- PMLiVE

MIT study reveals why certain immunotherapies do not always work

The findings could help doctors determine which drugs would benefit patients most

- PMLiVE

US study finds potential new way of improving immunotherapy for tumours

‘Warming up’ cold tumours assisted immunotherapy in tackling tumours

- PMLiVE

Takeda and F-star announce immunotherapy partnership worth over $1bn

Both companies will research and develop antibodies for new immuno-oncology targets

- PMLiVE

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment

Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?

Say Communications

- PMLiVE

Sanofi set to acquire Kiadis for €308m

Acquisition will see French pharma gain access to NK-cell platform

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links